CIMB Reiterates Reduce Rating for Sirtex Medical Limited (SRX)
Sirtex Medical Limited (ASX:SRX)‘s stock had its “reduce” rating reaffirmed by stock analysts at CIMB in a report issued on Sunday, AnalystRatingsNetwork reports.
Sirtex Medical Limited (ASX:SRX) opened at 14.000 on Friday. Sirtex Medical Limited has a 52-week low of A$9.360 and a 52-week high of A$14.590. The stock has a 50-day moving average of A$12.30 and a 200-day moving average of A$12.49. The company has a market cap of A$785.1 million and a price-to-earnings ratio of 43.59.
Sirtex Medical Limited is a biotechnology and medical device company. The Company is engaged in manufacturing and to distribute liver cancer treatments utilizing particle technology to approved markets in Asia-Pacific, Europe and the United States.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.